Furthermore, three cases demonstrated a prolonged period of survival (coma) between insulin administration and death allowing time for insulin to be degraded, or the administration of rapid-acting insulin which is also rapidly degraded. The gene discussed is INS; the disease is type 2 diabetes mellitus.